Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How has the atypical hemolytic uremic syndrome treatment market size changed in recent years, and what is the outlook ahead?
The atypical hemolytic uremic syndrome treatment market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increased clinical trials, growing disease awareness, government support for research, improved diagnostic capabilities, and increasing disease incidence.
The atypical hemolytic uremic syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $2.34 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to government support initiatives, focus on complement dysregulation, growing patient awareness, increase in treatment availability, and enhanced diagnostic techniques. Major trends in the forecast period include next-generation complement inhibitors, digital health monitoring and AI tools, AI-driven drug discovery, personalized medicine, and genotyping and biomarker-based diagnostics.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24156&type=smp
What are the top economic and technological drivers pushing atypical hemolytic uremic syndrome treatment market growth?
The rising demand for targeted therapies is expected to propel the growth of the atypical hemolytic uremic syndrome treatment market going forward. Targeted therapies refer to the medical treatments that specifically target and interfere with molecular pathways involved in the growth and spread of diseases. The rising demand for targeted therapies is due to their ability to provide more precise treatments with fewer side effects, improve patient outcomes, and offer alternatives to traditional, less specific therapies. Atypical hemolytic uremic syndrome (aHUS) treatment supports targeted therapies by specifically blocking the overactivation of the complement system, which is the root cause of the disease, allowing for precise intervention that minimizes damage to blood vessels and kidneys. For instance, in October 2023, according to NHS England, a UK-based government agency, in England, 11 million hormone replacement therapy (HRT) items were prescribed, up 47% from 2021–22, with around 2.3 million patients receiving prescriptions, marking a 29% year-on-year increase. Therefore, the rising demand for targeted therapies is driving growth in the atypical hemolytic uremic syndrome treatment market.
How is the atypical hemolytic uremic syndrome treatment market segmented by product, application, and end-user?
The atypical hemolytic uremic syndrome treatment market covered in this report is segmented –
1) By Treatment Type: Complement Inhibitors, Plasma Exchange Therapy, Supportive Care, Antibiotics
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Technology: Genetic Testing And Diagnostic Tools, Realtime Monitoring And Complement Activation Technologies, Treatment Delivery Systems, Digital Health Solutions
4) By End User: Hospital, Speciality Clinics, Home care Settings, Ambulatory Care Centres
Subsegments:
1) By Complement Inhibitors: Eculizumab, Ravulizumab, C5 Inhibitors, Factor H Inhibitors, Other Complement Inhibitors
2) By Plasma Exchange Therapy: Fresh Frozen Plasma (FFP) Exchange, Therapeutic Plasma Exchange (TPE), Plasma Filtration, Other Plasma Exchange Techniques
3) By Supportive Care: Dialysis, Kidney Transplantation, Red Blood Cell Transfusions, Platelet Transfusions, Anticoagulants, Other Supportive Therapies
4) By Antibiotics: Broad-Spectrum Antibiotics, Targeted Antibiotics, Prophylactic Antibiotics, Other Antibiotic Treatments
View The Full Market Report:
What evolving trends are creating new opportunities in the atypical hemolytic uremic syndrome treatment market?
Major companies operating in the atypical hemolytic uremic syndrome treatment market are focusing on developing innovative therapies, such as monoclonal antibody drugs, to enhance targeted complement inhibition and improve patient outcomes. Monoclonal antibody drugs are laboratory-made proteins that mimic the immune system’s ability to fight harmful pathogens by specifically targeting and binding to certain proteins involved in disease processes. For instance, in January 2025, AstraZeneca Pharma India Limited, an India-based biopharmaceutical company, received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell, and distribute eculizumab (marketed as Soliris) in India. These monoclonal antibodies specifically bind to complement protein C5, inhibiting its cleavage and thus blocking the formation of the terminal complement complex involved in immune-mediated cell destruction. It is used to treat rare and severe conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and neuromyelitis optica spectrum disorder by preventing complement-mediated damage.
Which leading companies are dominating the atypical hemolytic uremic syndrome treatment market landscape?
Major companies operating in the atypical hemolytic uremic syndrome treatment market are F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Alnylam Pharmaceuticals Inc., Vifor Pharma Ltd., Samsung Bioepis Co. Ltd., Fuji Pharma Co. Ltd., Aevitas Therapeutics Inc., Pharmasyntez JSC, Omeros Corporation, ChemoCentryx Inc., ISU Abxis Co. Ltd., Greenovation Biotech GmbH, Akari Therapeutics plc, NovelMed Therapeutics Inc., Eleva GmbH.
Which geographic areas are expected to offer the highest growth opportunities in theatypical hemolytic uremic syndrome treatment market?
North America was the largest region in the atypical hemolytic uremic syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atypical hemolytic uremic syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Atypical Hemolytic Uremic Syndrome Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24156&type=smp
Need Customized Data On Atypical Hemolytic Uremic Syndrome Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24156&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
